Ad is loading...
RCKT
Price
$13.88
Change
+$0.56 (+4.20%)
Updated
Dec 6, 04:59 PM (EDT)
88 days until earnings call
RYTM
Price
$58.84
Change
+$1.02 (+1.76%)
Updated
Dec 6, 04:59 PM (EDT)
86 days until earnings call
Ad is loading...

RCKT vs RYTM

Header iconRCKT vs RYTM Comparison
Open Charts RCKT vs RYTMBanner chart's image
Rocket Pharmaceuticals
Price$13.88
Change+$0.56 (+4.20%)
Volume$9.25K
CapitalizationN/A
Rhythm Pharmaceuticals
Price$58.84
Change+$1.02 (+1.76%)
Volume$4.59K
CapitalizationN/A
RCKT vs RYTM Comparison Chart
Loading...
RCKT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RYTM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
RCKT vs. RYTM commentary
Dec 08, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RCKT is a StrongBuy and RYTM is a StrongSell.

COMPARISON
Comparison
Dec 08, 2024
Stock price -- (RCKT: $13.89 vs. RYTM: $58.89)
Brand notoriety: RCKT and RYTM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RCKT: 78% vs. RYTM: 66%
Market capitalization -- RCKT: $1.21B vs. RYTM: $3.55B
RCKT [@Biotechnology] is valued at $1.21B. RYTM’s [@Biotechnology] market capitalization is $3.55B. The market cap for tickers in the [@Biotechnology] industry ranges from $489.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.71B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RCKT’s FA Score shows that 0 FA rating(s) are green whileRYTM’s FA Score has 1 green FA rating(s).

  • RCKT’s FA Score: 0 green, 5 red.
  • RYTM’s FA Score: 1 green, 4 red.
According to our system of comparison, RYTM is a better buy in the long-term than RCKT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RCKT’s TA Score shows that 6 TA indicator(s) are bullish while RYTM’s TA Score has 5 bullish TA indicator(s).

  • RCKT’s TA Score: 6 bullish, 2 bearish.
  • RYTM’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, RCKT is a better buy in the short-term than RYTM.

Price Growth

RCKT (@Biotechnology) experienced а -3.47% price change this week, while RYTM (@Biotechnology) price change was -5.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.01%. For the same industry, the average monthly price growth was -2.68%, and the average quarterly price growth was +10.76%.

Reported Earning Dates

RCKT is expected to report earnings on Mar 06, 2025.

RYTM is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (-1.01% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RYTM($3.55B) has a higher market cap than RCKT($1.21B). RYTM YTD gains are higher at: 28.105 vs. RCKT (-53.654). RYTM (-237.01M) and RCKT (-247.25M) have comparable annual earnings (EBITDA) . RYTM has more cash in the bank: 298M vs. RCKT (236M). RYTM has less debt than RCKT: RYTM (4.03M) vs RCKT (25.6M). RYTM has higher revenues than RCKT: RYTM (113M) vs RCKT (0).
RCKTRYTMRCKT / RYTM
Capitalization1.21B3.55B34%
EBITDA-247.25M-237.01M104%
Gain YTD-53.65428.105-191%
P/E RatioN/AN/A-
Revenue0113M-
Total Cash236M298M79%
Total Debt25.6M4.03M635%
FUNDAMENTALS RATINGS
RCKT vs RYTM: Fundamental Ratings
RCKT
RYTM
OUTLOOK RATING
1..100
688
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
99
Overvalued
PROFIT vs RISK RATING
1..100
10032
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
8942
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCKT's Valuation (43) in the Biotechnology industry is somewhat better than the same rating for RYTM (99). This means that RCKT’s stock grew somewhat faster than RYTM’s over the last 12 months.

RYTM's Profit vs Risk Rating (32) in the Biotechnology industry is significantly better than the same rating for RCKT (100). This means that RYTM’s stock grew significantly faster than RCKT’s over the last 12 months.

RCKT's SMR Rating (97) in the Biotechnology industry is in the same range as RYTM (99). This means that RCKT’s stock grew similarly to RYTM’s over the last 12 months.

RYTM's Price Growth Rating (42) in the Biotechnology industry is somewhat better than the same rating for RCKT (89). This means that RYTM’s stock grew somewhat faster than RCKT’s over the last 12 months.

RYTM's P/E Growth Rating (100) in the Biotechnology industry is in the same range as RCKT (100). This means that RYTM’s stock grew similarly to RCKT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RCKTRYTM
RSI
ODDS (%)
Bullish Trend 3 days ago
86%
Bearish Trend 3 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
73%
Momentum
ODDS (%)
Bullish Trend 3 days ago
87%
Bearish Trend 3 days ago
81%
MACD
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
78%
Advances
ODDS (%)
Bullish Trend 7 days ago
83%
Bullish Trend 12 days ago
81%
Declines
ODDS (%)
Bearish Trend 18 days ago
82%
Bearish Trend 6 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 4 days ago
73%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
79%
View a ticker or compare two or three
Ad is loading...
RCKT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RYTM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CCAPX14.610.04
+0.27%
FS Chiron Capital Allocation Class I
RWMAX64.800.03
+0.05%
American Funds Washington Mutual R1
ABEMX14.04N/A
N/A
abrdn Emerging Markets Instl
AFCGX18.04-0.01
-0.06%
American Century Focused Intl Gr G
PMFKX11.93-0.02
-0.17%
Pioneer Multi-Asset Income K

RCKT and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCKT has been loosely correlated with DNLI. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if RCKT jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCKT
1D Price
Change %
RCKT100%
+4.28%
DNLI - RCKT
53%
Loosely correlated
+6.73%
NTLA - RCKT
53%
Loosely correlated
+7.84%
AXON - RCKT
52%
Loosely correlated
-0.30%
FATE - RCKT
52%
Loosely correlated
+11.34%
PRME - RCKT
51%
Loosely correlated
+10.10%
More

RYTM and

Correlation & Price change

A.I.dvisor indicates that over the last year, RYTM has been loosely correlated with RCKT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if RYTM jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RYTM
1D Price
Change %
RYTM100%
+1.85%
RCKT - RYTM
49%
Loosely correlated
+4.28%
ERAS - RYTM
43%
Loosely correlated
+4.48%
XENE - RYTM
42%
Loosely correlated
+3.16%
PLRX - RYTM
42%
Loosely correlated
+2.87%
IDYA - RYTM
41%
Loosely correlated
+5.38%
More